Source BioScience PLC Additional Listing (2567E)
November 02 2015 - 10:17AM
UK Regulatory
TIDMSBS
RNS Number : 2567E
Source BioScience PLC
02 November 2015
2 November 2015
Source BioScience plc
(or "the Company")
Additional Listing on Exercise of Share Options
Source BioScience plc (LSE: SBS) announces that it has issued
124,564 new Ordinary Shares of 2 pence each in the Company ("New
Ordinary Shares"), following net exercise of share options by
employees under the Company's 2001 Approved Share Option
Scheme.
Application has been made for the new Ordinary Shares to be
admitted to the Official List of the UK Listing Authority and to
trading on the Main Market of the London Stock Exchange. Admission
of the new Ordinary Shares will occur as soon as reasonably
practical.
Following the issue and allotment, the Company's issued share
capital will comprise 349,261,105 Ordinary Shares of 2 pence each.
This figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or change to their interest in, the
Company under the FCA's Disclosure and Transparency Rules. The new
Ordinary Shares will rank pari passu with existing Ordinary
Shares.
Enquiries
Source BioScience plc
Dr Nick Ash, Company Secretary
Tel: +44 (0) 115 973 9010
Email: enquiries@sourcebioscience.com
www.sourcebioscience.com
About Source BioScience:
Source BioScience plc (LSE: SBS) is a trusted provider of state
of the art laboratory services and products to the healthcare and
clinical, life and applied sciences and biopharma industries. It is
an international business operating ten state of the art facilities
in five countries and with customers in over 90 countries
worldwide. The Group offers a complementary portfolio of laboratory
services and products that share common technologies, laboratory
processes, infrastructure and expertise. These include clinical
diagnostics, genomics, proteomics, drug discovery and development
research as well as controlled environment storage and testing
services for a diverse range of markets. These services and
products are provided to a large and diverse customer base
including the top 50 pharmaceutical companies, leading universities
and research institutes worldwide, the UK NHS and other healthcare
providers. The Group is listed on the Premium Main Market of the
London Stock Exchange.
This information is provided by RNS
The company news service from the London Stock Exchange
END
LISELLFBEFFFFBX
(END) Dow Jones Newswires
November 02, 2015 10:17 ET (15:17 GMT)
Medical Solutions (LSE:MLS)
Historical Stock Chart
From Apr 2024 to May 2024
Medical Solutions (LSE:MLS)
Historical Stock Chart
From May 2023 to May 2024
